Mission Early

Mission Early is a global initiative uniting partners to improve early cancer detection, diagnosis, and treatment through policy guidance, evidence, and collaboration.

Launched in 2024, Mission Early is a multi-stakeholder initiative to increase early detection, timely diagnosis and early-stage treatment of cancer with a focus on high-incidence cancers, including breast, lung, and prostate.

Mission Early develops policy evidence, disseminates best practices and provides recommendations for policy action to bring the highest possible standard of early cancer care to everyone.  

The initiative aligns and supports key targets in the World Cancer Declaration 2025–2035: 60% of cancers are diagnosed at an early stage and 80% of cancer-care facilities have access to essential medicines and technologies by 2035. 

The initiative is currently governed by a Steering Group (SG), comprised of founding members (UICC, All.Can, Cancer Patients Europe and MSD) and an expert advisor.

Research and advocacy 

To date, Mission Early has commissioned several research studies focusing on:  

In parallel, Mission Early partners have supported advocacy activities aimed at influencing policy change related to early detection, treatment and care among national and regional decision makers in Europe (EU, Spain and Romania) and Latin America (Mexico). 

In November 2025, Mission Early launched a Call to Action for Better Early Cancer Care, targeted at global cancer policymakers​. There are 15 signatories to date, including national and global health organisations, patient advocacy groups and industry partners. 

What is UICC's role?

UICC is a founding member and assumed Secretariat duties for ME in April 2026 to support transitioning the initiative from research to implementation of policy-focused advocacy activities at the global, regional and national levels.

Mission Early sessions highlighting research findings and recommendations have been featured at key UICC events, including the WCC 2024, World Cancer Leaders’ Summit 2025 and the Cancer Planner’s Forum 2026.  

 
 
Middle Eastern man in shirt and trousers in front of a radiotherapy machine

Muhammad Yaseen, a UICC Technical Fellow working at the Lady Reading Hospital in Pakistan, describes how a free, automated quality control software can make imaging equipment more reliable, and help detect cancers earlier.

Strengthening early cancer detection through...

two men wearing headphones with mics, smiling, one without hair, a cancer patient

When Joey Barnes was diagnosed with testicular cancer, he responded with humour, a podcast, and a promise to speak openly about a disease many men never discuss. After his death, his mother founded Having a Ball, a UICC member organisation, to keep that message alive

“If I can save one other man from going through...

UICC Podcast N7_2026 - Innovative approaches to cancer awareness
In this new Let’s Talk Cancer episode, Elize Joubert, CEO of the Cancer Association of South Africa (CANSA), a UICC member, discusses how innovative partnerships, community engagement and patient support services are helping to improve cancer awareness, early detection and care across South Africa.

Podcast "Let’s Talk Cancer" – Innovative...

Mission Early's Steering Group

Cancer Patients Europe (CPE) is dedicated to representing and empowering the voices of cancer patients and cancer survivors, advocating for their needs and rights at every stage of the cancer journey. Beyond advocacy, CPE works closely with policymakers, healthcare professionals and other stakeholders to help shape policies that promote cancer prevention, access to high-quality care and treatment, and support for survivorship.
 
 
 

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

Learn more

Founded in 1933 and based in Geneva, UICC has over 1150 member organisations in 172 countries and territories. The membership base includes the world’s major cancer leagues and societies, research institutes, treatment centres, hospitals, ministries of health, public health agencies and patient support groups. UICC’s mission is to both unite and support the cancer community in its efforts to reduce the global cancer burden, promote greater equity and ensure that cancer control remains a priority on the global health and development agenda. 

Partners

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

Learn more

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.

Last update

Thursday 27 August 2026

Share this page